EUVIMEDEUVIMED entdecken
Open Access

Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts

Medikation zur Behandlung von Opioidkonsumstörung nach schweren injektionsbedingten Infektionen in Massachusetts

Simeon D Kimmel, Alexander Y Walley, Laura F White, Shapei Yan, Christine Grella, Adam Majeski, Michael D Stein, Amy Bettano, Dana Bernson, Mari-Lynn Drainoni, Jeffrey H Samet, Marc R Larochelle

JAMA Network Open · 24.07.2024 · 7 (7) · e2421740

DOI: 10.1001/jamanetworkopen.2024.21740 ↗

Auf einen Blick

Bei 9.757 Personen nach SIRI-Hospitalisierung erhielten 47,7 % innerhalb von 12 Monaten MOUD. Rehospitalisierung und Sterblichkeit waren häufig.

Fragestellung

Wie häufig werden nach einer Hospitalisierung wegen schwerer injektionsbedingter Infektionen MOUD, Rehospitalisierung und Tod erfasst, und welche Faktoren sind mit MOUD verbunden?

Methode

Retrospektive Kohortenstudie mit Massachusetts Public Health Data Warehouse; Erwachsene 18 bis 64 Jahre mit Opioidkonsumstörung und SIRI-Hospitalisierung zwischen 1. Juli 2014 und 31. Dezember 2019.

Ergebnisse

Von 9.757 Überlebenden erhielten 4.652 (47,7 %) MOUD, 6.518 (66,8 %) wurden rehospitalisiert und 1.068 (10,9 %) starben innerhalb von 12 Monaten. Vorherige MOUD war stark mit MOUD nach Entlassung assoziiert.

Schlussfolgerung der Autor:innen

Die Autor:innen berichten, dass im Jahr nach einer SIRI-Hospitalisierung Mortalität und Rehospitalisierung häufig waren und nur etwa die Hälfte MOUD erhielt. MOUD vor der SIRI war mit MOUD nach der Hospitalisierung verbunden.

Kernaussagen

  • 47,7 % erhielten innerhalb von 12 Monaten MOUD
  • 66,8 % wurden rehospitalisiert, 10,9 % starben
  • MOUD vor der SIRI sagte MOUD nach Entlassung voraus

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 24.07.2024. Verfasst von Simeon D Kimmel und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, B…. Hauptthemen laut MEDLINE: Opioid-Related Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Serious injection-related infections (SIRIs) cause significant morbidity and mortality. Medication for opioid use disorder (MOUD) improves outcomes but is underused. Understanding MOUD treatment after SIRIs could inform interventions to close this gap.

Objectives

To examine rehospitalization, death rates, and MOUD receipt for individuals with SIRIs and to assess characteristics associated with MOUD receipt. Design, Setting, and Participants This retrospective cohort study used the Massachusetts Public Health Data Warehouse, which included all individuals with a claim in the All-Payer Claims Database and is linked to individual-level data from multiple government agencies, to assess individuals aged 18 to 64 years with opioid use disorder and hospitalization for endocarditis, osteomyelitis, epidural abscess, septic arthritis, or bloodstream infection (ie, SIRI) between July 1, 2014, and December 31, 2019. Data analysis was performed from November 2021 to May 2023. Exposure Demographic and clinical factors potentially associated with posthospitalization MOUD receipt. Main Outcomes and Measures The main outcome was MOUD receipt measured weekly in the 12 months after hospitalization. We used zero-inflated negative binomial regression to examine characteristics associated with any MOUD receipt and rates of treatment in the 12 months after hospitalization. Secondary outcomes were receipt of any buprenorphine formulation, methadone, and extended-release naltrexone examined individually.

Results

Among 9757 individuals (mean [SD] age, 43.3 [12.1] years; 5701 [58.4%] male) who survived a SIRI hospitalization, 4652 (47.7%) received MOUD, 6518 (66.8%) were rehospitalized, and 1068 (10.9%) died within 12 months. Of those treated with MOUD in the 12 months after hospitalization, the mean (SD) number of MOUD initiations during follow-up was 3.0 (1.8), with 985 of 4652 individuals (21.2%) receiving treatment at least 80% of the time. MOUD treatment after SIRI hospitalization was significantly associated with MOUD in the prior 6 months (buprenorphine: adjusted odds ratio [AOR], 16.63; 95% CI, 14.04-19.71; methadone: AOR, 28.61; 95% CI, 22.80-35.90; or naltrexone: AOR, 2.05; 95% CI, 1.58-2.66). Prior buprenorphine (incident rate ratio [IRR], 1.16; 95% CI, 1.09-1.22) or methadone (IRR, 1.90; 95% CI, 1.79-2.02) use was associated with higher treatment rates after hospitalization, and prior naltrexone use (IRR, 0.85; 95% CI, 0.77-0.95) was associated with lower rates. Conclusions and Relevance This study found that in the year after a SIRI hospitalization in Massachusetts, mortality and rehospitalization were common, and only half of patients received MOUD. Treatment with MOUD before a SIRI was associated with posthospitalization MOUD initiation and time receiving MOUD. Efforts are needed to initiate MOUD treatment during SIRI hospitalizations and subsequently retain patients in treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersHumansMassachusettsMaleFemaleAdultRetrospective StudiesMiddle AgedBuprenorphineOpiate Substitution TreatmentSubstance Abuse, IntravenousMethadoneAdolescentYoung AdultPatient ReadmissionHospitalizationNaltrexone

Substanzen

BuprenorphineMethadoneNaltrexone

Autor:innen und Institutionen

  • Section of General Internal Medicine, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.
  • Section of Infectious Diseases, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.
  • Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
  • Semel Institute of Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles.
  • Lighthouse Institute, Chestnut Health Systems, Chicago, Illinois.
  • Department of Health, Law and Policy, Boston University School of Public Health, Boston, Massachusetts.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Kimmel, S. D., Walley, A. Y., White, L. F., Yan, S., Grella, C., Majeski, A., Stein, M. D., Bettano, A., Bernson, D., Drainoni, M. L., Samet, J. H., & Larochelle, M. R. (2024). Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts. JAMA Network Open, 7(7), e2421740. https://doi.org/10.1001/jamanetworkopen.2024.21740

Vancouver

Kimmel SD, Walley AY, White LF, Yan S, Grella C, Majeski A, et al. Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts. JAMA Network Open. 2024;7(7):e2421740. doi:10.1001/jamanetworkopen.2024.21740

BibTeX
@article{Kimmel2024,
  author = {Kimmel, Simeon D and Walley, Alexander Y and White, Laura F and Yan, Shapei and Grella, Christine and Majeski, Adam and Stein, Michael D and Bettano, Amy and Bernson, Dana and Drainoni, Mari-Lynn and Samet, Jeffrey H and Larochelle, Marc R},
  title = {Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {7},
  pages = {e2421740},
  doi = {10.1001/jamanetworkopen.2024.21740}
}
Kostenlos starten →